NYXH.US Nyxoah

Healthcare Health Care Equipment & Supplies USA Stocks
0.8995 USD
Close of Nov 15, 2026
0.8000 5.39
Market cap
USD 91.6M
P/E
-
P/B
1.22x
ROE
-135.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NYXH.US undervalued?

Graham number

The Graham number of Nyxoah cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nyxoah fundamental analysis

No fundamental analysis for Nyxoah yet.

Nyxoah stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Full company profile